Precision Biosciences Stock Price, News & Analysis

Precision BioSciences, Inc. (Nasdaq: DTIL) has announced its participation in the H.C. Wainwright Global Investment Conference on May 24, 2022. The company will also publish its financial results for the first quarter of 2022 and provide a business update on May 9, 2022. The conference presentation will be available on-demand starting at 7:00 AM ET. Precision BioSciences is focused on developing innovative CAR T therapies and gene editing platforms using its proprietary ARCUS technology.

Precision BioSciences (DTIL) announced significant advancements in gene editing and CAR T therapies. For 2021, revenues surged to $115.5 million, up from $24.3 million in 2020, attributed to strategic partnerships with Servier, Lilly, and iECURE. R&D expenses rose to $115.2 million from $98.1 million, reflecting investments in its innovative ARCUS platform. The net loss narrowed to $30.6 million, or $(0.52) per share. Going forward, the company aims to advance three in vivo programs to IND in three years and updates on allogenic CAR T clinical studies are anticipated in mid-2022.

Precision BioSciences, Inc. (Nasdaq: DTIL) will publish its financial results for Q4 and fiscal year 2021 on March 15, 2022, alongside a business update. The company focuses on developing ARCUS®-based ex vivo CAR T and in vivo gene editing therapies aimed at treating genetic and infectious diseases lacking adequate treatments. With its proprietary ARCUS platform, Precision BioSciences aims for therapeutic safety and control.

Atomwise, a leader in AI-driven small molecule drug discovery, has appointed David Thomson, Ph.D., as Chief Scientific Officer, alongside Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D., as General Counsel. Dr. Thomson will spearhead the company's drug development strategy, focusing on enhancing their small molecule pipeline. His extensive experience includes leadership roles at Precision BioSciences and Shire. Barr brings expertise from Bridge Bio, where he managed significant capital raises. Cerio has a strong legal background from Moderna. The team aims to advance Atomwise's innovative drug discovery capabilities.

Precision BioSciences (Nasdaq: DTIL) announced that CEO Michael Amoroso will provide a corporate update at the annual J.P. Morgan Health Care Conference on January 12, 2022, from 2:15 - 2:55 PM ET. He will be joined by co-founder Derek Jantz, CFO Alex Kelly, and CMO Alan List for a Q&A session. The presentation will be available via a live webcast on the company's website, along with archived materials. Precision BioSciences is focused on developing innovative CAR T therapies using its proprietary ARCUS genome editing platform.

Precision BioSciences has announced an agreement with a syndicate led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary into an independent entity. This strategic move allows Elo to focus on food and agriculture, while Precision BioSciences can concentrate on human therapeutics utilizing its ARCUS® genome editing platform. Precision maintains an equity stake in Elo, and all employees transitioned to the new company. The separation aims to enhance operational success for both entities.

Precision BioSciences (DTIL) has reported promising updates on its allogeneic CAR T cell therapies, PBCAR0191 and PBCAR19B. In a Phase 1/2a study, PBCAR0191 showed a 73% overall response rate and a 59% complete response rate among heavily pre-treated patients. Notably, 100% of patients who had prior autologous CAR T therapy responded to PBCAR0191. The company is also progressing with PBCAR19B, which aims to be a best-in-class CD19 therapy. As of November 30, 2021, Precision holds approximately $152 million in cash, supporting operations into 2023.

Precision BioSciences, Inc. (DTIL) announced an upcoming webcast on December 11, 2021, at 7:30 PM ET to review interim data on the PBCAR0191 CD19 allogeneic CAR T program presented at the American Society of Hematology Annual Meeting. Key oral presentations include details on the efficacy of PBCAR0191 in relapsed/refractory B-cell malignancies, showcasing its therapeutic potential. The company aims to provide updates on its CAR T pipeline during this event, emphasizing its commitment to developing innovative gene editing therapies.

Precision BioSciences (NASDAQ: DTIL) announced the presentation of preclinical data on its chronic hepatitis B virus (HBV) program at the HEP DART 2021 conference in Cabo San Lucas, Mexico, from December 5-9, 2021.

The oral presentation, titled "Targeting Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo", is scheduled for December 6, 2021, at 11:25 AM ET. Preclinical research demonstrated that ARCUS technology reduced HBV s-antigen levels by 77% in infected human hepatocytes and achieved a durable 96% reduction in mouse models.